- Home
- CTNM vs CVRX Comparison
CTNM vs CVRX Comparison
Compare CTNM & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- CVRX
- Stock Information
- Founded
- CTNM 2009
- CVRX 2000
- Country
- CTNM United States
- CVRX United States
- Employees
- CTNM N/A
- CVRX N/A
- Industry
- CTNM
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CTNM
- CVRX Health Care
- Exchange
- CTNM Nasdaq
- CVRX Nasdaq
- Market Cap
- CTNM 174.6M
- CVRX 177.4M
- IPO Year
- CTNM 2024
- CVRX 2021
- Fundamental
- Price
- CTNM $7.38
- CVRX $7.03
- Analyst Decision
- CTNM Strong Buy
- CVRX Buy
- Analyst Count
- CTNM 4
- CVRX 7
- Target Price
- CTNM $22.50
- CVRX $14.00
- AVG Volume (30 Days)
- CTNM 196.1K
- CVRX 307.9K
- Earning Date
- CTNM 08-05-2025
- CVRX 08-04-2025
- Dividend Yield
- CTNM N/A
- CVRX N/A
- EPS Growth
- CTNM N/A
- CVRX N/A
- EPS
- CTNM N/A
- CVRX N/A
- Revenue
- CTNM N/A
- CVRX $54,652,000.00
- Revenue This Year
- CTNM N/A
- CVRX $11.53
- Revenue Next Year
- CTNM N/A
- CVRX $18.61
- P/E Ratio
- CTNM N/A
- CVRX N/A
- Revenue Growth
- CTNM N/A
- CVRX 23.11
- 52 Week Low
- CTNM $3.35
- CVRX $4.30
- 52 Week High
- CTNM $20.55
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- CTNM N/A
- CVRX 44.46
- Support Level
- CTNM N/A
- CVRX $6.15
- Resistance Level
- CTNM N/A
- CVRX $7.83
- Average True Range (ATR)
- CTNM 0.00
- CVRX 0.53
- MACD
- CTNM 0.00
- CVRX -0.10
- Stochastic Oscillator
- CTNM 0.00
- CVRX 33.08
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.